Alan A. Musso

CIK: 0001295830

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RACD

Research Alliance Corp IV

Director

FULC

Fulcrum Therapeutics, Inc.

Officer

ALRN

Aileron Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

FULC
Fulcrum Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (right to buy)
Direct
170K shares-
RNTX
Rein Therapeutics, Inc.
Jul 23, 2025
Award(A)
Stock Option (right to buy)
Direct
17.5K shares-
FULC
Fulcrum Therapeutics, Inc.
Jan 24, 2025
Award(A)
Stock Option (right to buy)
Direct
285K shares-
ALRN
Aileron Therapeutics, Inc.
Dec 2, 2024
Award(A)
Stock Option (right to buy)
Direct
35K shares-

		Type	Shares	Price		Ownership
Feb 2, 2026	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	170,000	-	-	Direct
Jul 23, 2025	RNTX Rein Therapeutics, Inc.	Award(A) Stock Option (right to buy)	17,500	-	-	Direct
Jan 24, 2025	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	285,000	-	-	Direct
Dec 2, 2024	ALRN Aileron Therapeutics, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct

1-4 of 4 transactions

About Musso Alan A

Musso Alan A (SEC CIK 0001295830) files insider reports with the SEC as Director of Research Alliance Corp IV (RACD), Chief Financial Officer of Fulcrum Therapeutics, Inc. (FULC) and Director of Aileron Therapeutics, Inc. (ALRN).

Signal8 holds 5 ownership filings by Musso Alan A (1 Form 3, 4 Form 4), filed between Dec 6, 2024 and Jul 10, 2026. Those filings report 4 transactions, from Dec 2, 2024 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Musso Alan A's filings is in CAMBRIDGE, MA.

Recent filings by Musso Alan A

Feb 2, 2026: Grant or award of FULC derivative securities (Form 4, code A).
Jul 23, 2025: Grant or award of RNTX derivative securities (Form 4, code A).
Jan 24, 2025: Grant or award of FULC derivative securities (Form 4, code A).
Dec 2, 2024: Grant or award of ALRN derivative securities (Form 4, code A).

Other insiders filing for Research Alliance Corp IV (RACD)

Research Alliance Holdings IV LLC, Director
Hammond Matthew, Chief Executive Officer
Stusnick Henry William, COO and CBO
Maslowski John Michael, Director
Adams Francis Sherman, Chief Financial Officer

How to read Form 4 transaction codes